Hoth Therapeutics Inc (HOTH) Stock Price, Quote & News

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 756 2997

Website: hoththerapeutics.com

Address:

1177 Avenue of the Americas, Suite 5066 5th Floor, New York, United States

MahiMe Jan. 9 at 8:15 PM

$HOTH As cancer treatments become more targeted and effective, patients are staying on therapies longer, but skin-related side effects often lead to pain, infection risk, or the need to stop treatment entirely. These patents establish Hoth's "oncodermatology" platform, positioning them as a potential first-in-class provider for supportive care in oncology. https://www.prnewswire.com/news-releases/hoth-therapeutics-expands-oncology-pipeline-with-dual-patent-filings-establishing-novel-oncology-dermatology-ip-platform-302651580.html#:~:text=As%20cancer%20treatments%20become%20more,unmet%20need%20in%20oncology%20care.

0 · Reply

MahiMe Jan. 9 at 8:13 PM

$HOTH The "price tag" is driven by several key developments in HOTH's clinical pipeline: Oncology/Dermatology Breakthroughs: In early January 2026, HOTH filed two provisional patents for its oncology-dermatology platform, which aims to treat skin toxicities caused by cancer therapies. https://www.prnewswire.com/news-releases/hoth-therapeutics-expands-oncology-pipeline-with-dual-patent-filings-establishing-novel-oncology-dermatology-ip-platform-302651580.html HT-KIT Platform: The company reported that its HT-KIT program surpassed preclinical milestones, which is a major step toward an Investigational New Drug (IND) application. Obesity Drug JV: A joint venture to commercialize a VA-invented obesity drug has added a new layer of potential value to their portfolio.

0 · Reply

Tino321 Jan. 9 at 12:49 AM

$HOTH let’s get the ball rolling

0 · Reply

robiein35 Jan. 9 at 12:06 AM

$HOTH show be in 3-4$ range by end of this year if at least one shows promising results . For me Dilution is big concern to advance them

0 · Reply

robiein35 Jan. 9 at 12:04 AM

$HOTH 2026 seems to be busy for Hoth Hoth expects to finalize its' KIT IND submission in 2026, followed by first-in-human studies. HT-ALZ Alzheimer’s Regulatory-facing package expected to mature in 2026 GDNF-Based Weight-Loss & Metabolic Program (VA Collaboration) Data in 2026 CLEER-001 Phase 2 HT-001 clinical data update

0 · Reply

BioTuesdays Jan. 5 at 8:20 PM

$HOTH has announced the filing of two U.S. provisional patent applications to expand its IP portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies https://biotuesdays.com/2026/01/05/hoth-expands-ip-portfolio-with-filing-of-two-patent-applications/

0 · Reply

Ice_Von_Shillingham Jan. 5 at 2:45 AM

$HOTH Way undervalued! To the point of ridiculousness.

1 · Reply

JohnTrack Jan. 2 at 10:30 PM

$HOTH checking if sellers chill!

0 · Reply

JohnTrack Jan. 2 at 8:27 PM

$HOTH Expands Oncology Pipeline https://www.rapidticker.com/news/hoth-hoth-therapeutics-expands-oncology-pipeline-a6c134

0 · Reply

Outtlaw Jan. 2 at 2:56 PM

$HOTH Will we ever hit $2 again?

0 · Reply

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Dec 3, 2025, 2:00 PM EST - 6 weeks ago

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Dec 1, 2025, 8:03 AM EST - 6 weeks ago

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Nov 20, 2025, 8:13 AM EST - 7 weeks ago

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Oct 27, 2025, 7:49 AM EDT - 2 months ago

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Oct 21, 2025, 8:23 AM EDT - 3 months ago

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Oct 8, 2025, 8:02 AM EDT - 3 months ago

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Oct 7, 2025, 7:57 AM EDT - 3 months ago

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Sep 24, 2025, 8:13 AM EDT - 4 months ago

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Sep 16, 2025, 8:14 AM EDT - 4 months ago

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Sep 10, 2025, 8:29 AM EDT - 4 months ago

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Sep 4, 2025, 8:16 AM EDT - 4 months ago

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Sep 2, 2025, 8:16 AM EDT - 4 months ago

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Jul 29, 2025, 7:58 AM EDT - 6 months ago

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Jul 22, 2025, 8:19 AM EDT - 6 months ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jun 25, 2025, 8:27 AM EDT - 7 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Jun 24, 2025, 10:36 AM EDT - 7 months ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 23, 2025, 8:03 AM EDT - 7 months ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 18, 2025, 1:34 PM EDT - 7 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 8:22 AM EDT - 7 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 16, 2025, 8:00 AM EDT - 7 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 12, 2025, 9:17 AM EDT - 7 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 11, 2025, 8:28 AM EDT - 7 months ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 7 months ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

May 12, 2025, 7:30 AM EDT - 8 months ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Apr 17, 2025, 8:01 AM EDT - 9 months ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 15, 2025, 8:19 AM EDT - 9 months ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 2, 2025, 8:02 AM EDT - 10 months ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 7:58 AM EDT - 10 months ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Mar 31, 2025, 4:45 PM EDT - 10 months ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 26, 2025, 8:02 AM EDT - 10 months ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 18, 2025, 8:06 AM EDT - 10 months ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 10, 2025, 8:02 AM EDT - 11 months ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 5, 2025, 1:40 PM EST - 11 months ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 4, 2025, 8:16 AM EST - 11 months ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Feb 10, 2025, 8:22 AM EST - 1 year ago

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Jan 24, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jan 21, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Jan 17, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Jan 8, 2025, 1:27 PM EST - 1 year ago

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Jan 7, 2025, 11:53 AM EST - 1 year ago

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Jan 7, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Dec 26, 2024, 7:58 AM EST - 1 year ago

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Nov 20, 2024, 7:38 AM EST - 1 year ago

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Oct 29, 2024, 12:43 PM EDT - 1 year ago

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Oct 15, 2024, 6:38 AM EDT - 1 year ago

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Sep 17, 2024, 7:57 AM EDT - 1 year ago

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Sep 5, 2024, 10:32 AM EDT - 1 year ago

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Sep 5, 2024, 8:03 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Aug 15, 2024, 8:04 AM EDT - 1 year ago

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

MahiMe Jan. 9 at 8:15 PM

0 · Reply

MahiMe Jan. 9 at 8:13 PM

0 · Reply

Tino321 Jan. 9 at 12:49 AM

$HOTH let’s get the ball rolling

0 · Reply

robiein35 Jan. 9 at 12:06 AM

$HOTH show be in 3-4$ range by end of this year if at least one shows promising results . For me Dilution is big concern to advance them

0 · Reply

robiein35 Jan. 9 at 12:04 AM

0 · Reply

BioTuesdays Jan. 5 at 8:20 PM

0 · Reply

Ice_Von_Shillingham Jan. 5 at 2:45 AM

$HOTH Way undervalued! To the point of ridiculousness.

1 · Reply

JohnTrack Jan. 2 at 10:30 PM

$HOTH checking if sellers chill!

0 · Reply

JohnTrack Jan. 2 at 8:27 PM

$HOTH Expands Oncology Pipeline https://www.rapidticker.com/news/hoth-hoth-therapeutics-expands-oncology-pipeline-a6c134

0 · Reply

Outtlaw Jan. 2 at 2:56 PM

$HOTH Will we ever hit $2 again?

0 · Reply

MrTicker Jan. 2 at 2:01 PM

$HOTH Hoth Therapeutics Files Two US Provisional Patents for Oncology-Focused Dermatology Platform; Shares Rise MT NEWSWIRES 7:57 AM ET 1/2/2026

0 · Reply

stonkmamma Jan. 2 at 1:51 PM

$HOTH https://www.prnewswire.com/news-releases/hoth-therapeutics-expands-oncology-pipeline-with-dual-patent-filings-establishing-novel-oncology-dermatology-ip-platform-302651580.html

0 · Reply

2TrustHim Jan. 2 at 1:22 PM

$HOTH https://finance.yahoo.com/news/hoth-therapeutics-expands-oncology-pipeline-131300139.html

0 · Reply

MrTicker Jan. 2 at 1:20 PM

$HOTH Hoth Therapeutics Expands Oncology Pipeline With Dual Patent Filings BENZINGA 7:20 AM ET 1/2/2026 The first provisional patent application, titled covering the topical treatment of radiation-induced skin toxicity in oncology patients. The second provisional patent application, titled addressing dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors.

0 · Reply

MrTicker Jan. 2 at 1:14 PM

$HOTH Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform PR NEWSWIRE 7:13 AM ET 1/2/2026

0 · Reply

RaphaelRapoport Jan. 2 at 12:58 PM

$HOTH Anyone familiar with Lutris Pharma and LUT014?

0 · Reply

Tino321 Jan. 2 at 10:26 AM

$HOTH let’s have a better year folks. Enough with the bs let’s get to 2$ 🎇

0 · Reply

stonkmamma Dec. 31 at 6:39 PM

$HOTH what the fuck

1 · Reply

SPYmyQQQ Dec. 31 at 2:04 PM

🚀 New Signal ✅ 🪙 $HOTH 🗓️ Dec 31, 2025 💵 Entry: $1.02 🎯 Target (Opt.): $1.18 (+15.69%) 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Condemor Dec. 31 at 11:06 AM

$HOTH looks like it could start moving

0 · Reply

Johnnyb1973 Dec. 30 at 12:20 AM

$HOTH Its dead AF in here. Lol!

1 · Reply

PSM_EmpowerTrading Dec. 29 at 2:21 PM

🌅 Watchlist part 2 ✅ $FTEL low $0.80 support; if above $1.00, potential to $1.30–$1.50 ✅ $TII mid $3.50 support; if above $4.00, potential to $4.40–$4.50 ✅ $DTCK low $0.40 support; if above $0.50, potential to $0.55–$0.60 🚨 The above tickers are NOT ideal for swing accumulation at current price 🚨 ✅ Ideal long entries are near current support 🎯 Ideal stop loss below support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $MRKR, $HOTH still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D

1 · Reply

Market Cap	16.45M
Revenue (ttm)	0.00
Net Income (ttm)	-8.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	114,000
Avg Vol	193,710
Day's Range	N/A - N/A
Shares Out	15.51M
Stochastic %K	35%
Beta	0.57
Analysts	Strong Sell
Price Target	$4.50